Immuneering Co. (NASDAQ:IMRX) Given Average Rating of "Hold" by Analysts

Immuneering Co. (NASDAQ:IMRX - Get Free Report) has been given a consensus rating of "Hold" by the eight research firms that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $12.80.

Several equities research analysts have weighed in on IMRX shares. Needham & Company LLC reaffirmed a "buy" rating and issued a $15.00 target price on shares of Immuneering in a research report on Thursday, November 14th. Morgan Stanley cut shares of Immuneering from an "equal weight" rating to an "underweight" rating in a report on Friday. Finally, Chardan Capital reissued a "buy" rating and set a $13.00 target price on shares of Immuneering in a research note on Wednesday, November 20th.

Hedge Funds Weigh In On Immuneering

Several hedge funds have recently made changes to their positions in the business. XTX Topco Ltd raised its position in shares of Immuneering by 37.3% during the second quarter. XTX Topco Ltd now owns 34,159 shares of the company's stock worth $44,000 after purchasing an additional 9,274 shares during the period. HighTower Advisors LLC raised its holdings in Immuneering by 21.4% during the 3rd quarter. HighTower Advisors LLC now owns 53,360 shares of the company's stock worth $132,000 after buying an additional 9,400 shares during the period. Vontobel Holding Ltd. purchased a new stake in Immuneering during the third quarter valued at about $25,000. Corsair Capital Management L.P. acquired a new position in shares of Immuneering in the third quarter worth about $25,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Immuneering in the second quarter worth approximately $44,000. Institutional investors and hedge funds own 67.65% of the company's stock.

Immuneering Trading Down 17.0 %

IMRX traded down $0.34 on Friday, hitting $1.64. 1,843,462 shares of the company's stock were exchanged, compared to its average volume of 2,144,889. The stock has a fifty day moving average of $2.06 and a two-hundred day moving average of $1.69. Immuneering has a twelve month low of $1.00 and a twelve month high of $8.41. The firm has a market cap of $50.77 million, a PE ratio of -0.83 and a beta of -0.33.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.